跳至主導覽
跳至搜尋
跳過主要內容
國立陽明交通大學研發優勢分析平台 首頁
English
中文
首頁
人員
單位
研究成果
計畫
獎項
活動
貴重儀器
影響
按專業知識、姓名或所屬機構搜尋
Angiotensin converting-enzyme inhibitors, angiotensin receptor blockers, and calcium channel blockers are associated with prolonged vascular access patency in uremic patients undergoing hemodialysis
Fu An Chen, Chih Chiang Chien, Yu Wei Chen, Yu Te Wu,
Chih Ching Lin
*
*
此作品的通信作者
醫學系內科學科
研究成果
:
Article
›
同行評審
27
引文 斯高帕斯(Scopus)
總覽
指紋
指紋
深入研究「Angiotensin converting-enzyme inhibitors, angiotensin receptor blockers, and calcium channel blockers are associated with prolonged vascular access patency in uremic patients undergoing hemodialysis」主題。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Keyphrases
Confidence Interval
100%
Hazard Ratio
100%
Angiotensin-converting Enzyme Inhibitor (ACEi)
100%
Angiotensin Receptor Blockers
100%
Maintenance Hemodialysis Patients
100%
Uremic Patients
100%
Vascular Access Patency
100%
Calcium Channel Blockers
100%
Arteriovenous Fistula
66%
Arteriovenous Graft
66%
Primary Patency
50%
Taiwan
16%
National Health Insurance Research Database (NHIRD)
16%
Patient Characteristics
16%
Comorbidity
16%
Cox Proportional Hazards Model
16%
Prospective Randomized Trial
16%
Maintenance Hemodialysis
16%
Cardioprotection
16%
Pharmacotherapy
16%
Vascular Graft Infection
16%
Long-term Hemodialysis
16%
Access Thrombosis
16%
Co-medication
16%
Dialysis Access
16%
Nursing and Health Professions
Hemodialysis
100%
Confidence Interval
100%
Hazard Ratio
100%
Vascular Access
100%
Dipeptidyl Carboxypeptidase Inhibitor
100%
Angiotensin Receptor Antagonist
100%
Calcium Channel Blocking Agent
100%
Arteriovenous Fistula
66%
Arteriovenous Graft
66%
National Health Insurance
16%
Drug Therapy
16%
Proportional Hazards Model
16%
Thrombosis
16%
Antihypertensive Agent
16%
Comorbidity
16%
Biochemistry, Genetics and Molecular Biology
Angiotensin-Converting Enzyme
100%
Hemodialysis
100%
Angiotensin Receptor
100%
Patency
100%
Enzyme Inhibitor
100%
Calcium Channel Blocker
100%
Comorbidity
14%
Drug Therapy
14%
Pharmacology, Toxicology and Pharmaceutical Science
Dipeptidyl Carboxypeptidase Inhibitor
100%
Angiotensin Receptor Antagonist
100%
Hemodialysis
100%
Calcium Channel Blocker
100%
Arteriovenous Fistula
66%
Pharmacotherapy
16%
Thrombosis
16%
Antihypertensive Agent
16%
Comorbidity
16%